Literature DB >> 30723888

Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.

Peter N Morcos1, Jiang Liu2, Gideon M Blumenthal3, Hong Zhao2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30723888     DOI： 10.1002/cpt.1340

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  1 in total

1.  Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Authors:  Joy C Hsu; Felix Jaminion; Elena Guerini; Bogdana Balas; Walter Bordogna; Peter N Morcos; Nicolas Frey
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.